Early Parkinson Disease
Key Points
Key Points
- The treatment options for the alleviation of motor symptoms in the early stages of Parkinson disease (PD) are based on the enhancement of dopaminergic tone with levodopa, monoamine oxidase inhibitors, dopamine agonists (DAs), or a combination thereof.
- The choice of initial treatment is influenced by the potential for neuropsychiatric adverse effects associated with DAs and dyskinesia and motor fluctuations associated with levodopa.
Treatment
...Treatm...
Levo...
...uld counsel patients with early PD on the benefi...
...th early PD who seek treatment for motor...
...inicians may prescribe DAs as the initial dopamin...
...s should not prescribe DAs to patients wit...
...Prescribing le...
...should initially prescribe immediate-rel...
...ts with early PD, clinicians should prescribe th...
...nicians should routinely monitor patients taking...
...inicians should counsel patients taking...
Clinicians should counsel patients that i...
...Prescribing D...
...ns should inform the patient and caregiv...
...linicians should screen patients f...
...ould screen patients for the presence...
...cians should involve caregivers in ass...
...creen patients for the presence of adverse effe...
...should integrate patient preferences concerning...
...ns should prescribe the lowest dose...
...Taperin...
...inicians should recommend tapering...
...t be discontinued due to adverse eff...
...Prescr...
...nicians should counsel patients with early PD on...
...ns may prescribe MAO-B inhibitors as the initial...
...or Parkinson Disease Agen...